HK1207109A1 - Methods and compositions for treating amyloid deposits - Google Patents

Methods and compositions for treating amyloid deposits Download PDF

Info

Publication number
HK1207109A1
HK1207109A1 HK15107526.1A HK15107526A HK1207109A1 HK 1207109 A1 HK1207109 A1 HK 1207109A1 HK 15107526 A HK15107526 A HK 15107526A HK 1207109 A1 HK1207109 A1 HK 1207109A1
Authority
HK
Hong Kong
Prior art keywords
mammal
compositions
methods
csf
amyloid deposits
Prior art date
Application number
HK15107526.1A
Other languages
English (en)
Chinese (zh)
Inventor
Beverly L. Davidson
Bradley T. Hyman
Original Assignee
The General Hospital Corporation
University Of Iowa Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, University Of Iowa Research Foundation filed Critical The General Hospital Corporation
Publication of HK1207109A1 publication Critical patent/HK1207109A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15107526.1A 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits HK1207109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
US61/648,801 2012-05-18
PCT/US2013/031725 WO2013172964A1 (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Publications (1)

Publication Number Publication Date
HK1207109A1 true HK1207109A1 (en) 2016-01-22

Family

ID=49584137

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107526.1A HK1207109A1 (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Country Status (12)

Country Link
US (1) US20150183850A1 (https=)
EP (1) EP2850195B1 (https=)
JP (2) JP6469000B2 (https=)
CN (2) CN104540952A (https=)
AU (1) AU2013263346B2 (https=)
BR (1) BR112014028666B1 (https=)
CA (1) CA2873890C (https=)
ES (1) ES2786078T3 (https=)
HK (1) HK1207109A1 (https=)
IN (1) IN2014KN02672A (https=)
RU (1) RU2673484C2 (https=)
WO (1) WO2013172964A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
US20180161395A1 (en) * 2015-06-12 2018-06-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
CN109072274A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体（aspd）样结构体及医药组合物
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
AU2017306558B2 (en) * 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
JP7610923B2 (ja) * 2016-09-02 2025-01-09 スパーク セラピューティクス インコーポレイテッド Ｃｎｓ障害を治療するための方法及びベクター
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
CN112501208A (zh) 2017-10-03 2021-03-16 普利维尔治疗公司 用于溶酶体障碍的基因疗法
BR112020006661A2 (pt) 2017-10-03 2020-10-13 Prevail Therapeutics, Inc. terapias de genes para distúrbios lipossomais
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス，インコーポレーテッド 神経変性疾患のための遺伝子治療
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
BR112022019864A2 (pt) * 2020-03-31 2022-11-16 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Composto de oxofenilarsina deuterada e uso do mesmo
KR20230112672A (ko) * 2020-11-25 2023-07-27 프리베일 테라퓨틱스, 인크. 신경변성 질환을 위한 유전자 요법
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
CN116063405B (zh) * 2022-09-27 2025-08-29 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6468524B1 (en) * 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
JP5136766B2 (ja) * 2004-12-15 2013-02-06 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラベクター
CA2606490C (en) * 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
CN102886052B (zh) * 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
EP2154969B1 (en) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
EP3444346B1 (en) * 2010-04-23 2022-07-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders

Also Published As

Publication number Publication date
CA2873890C (en) 2022-12-06
RU2673484C2 (ru) 2018-11-27
CN104540952A (zh) 2015-04-22
CN112574964A (zh) 2021-03-30
EP2850195B1 (en) 2020-01-22
US20150183850A1 (en) 2015-07-02
RU2014151218A (ru) 2016-07-10
AU2013263346A1 (en) 2014-12-04
JP6469000B2 (ja) 2019-02-13
EP2850195A4 (en) 2015-12-09
BR112014028666A2 (pt) 2017-06-27
IN2014KN02672A (https=) 2015-05-08
AU2013263346B2 (en) 2018-08-23
BR112014028666B1 (pt) 2021-12-07
JP2019031564A (ja) 2019-02-28
EP2850195A1 (en) 2015-03-25
ES2786078T3 (es) 2020-10-08
WO2013172964A1 (en) 2013-11-21
CA2873890A1 (en) 2013-11-21
JP2015520161A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
HK1207109A1 (en) Methods and compositions for treating amyloid deposits
CA2832151C (en) Methods and compositions for treating brain diseases
HK1244299A1 (zh) 治疗肌萎缩侧索硬化(als)的组合物和方法
WO2015013148A3 (en) Methods and compositions for treating brain diseases
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
WO2011133890A8 (en) Cns targeting aav vectors and methods of use thereof
MX2020005282A (es) Vector para la produccion de particulas aav.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
WO2015109124A3 (en) Immunomodulatory agents
AR093355A1 (es) Composiciones y metodos para tratar proteinopatias
EP4219727A3 (en) Products and methods for treatment of amyotrophic lateral sclerosis
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
EA201692206A1 (ru) Векторы на основе aav для генной терапии в сетчатке и cns
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
MX388146B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
EP4491733A3 (en) Modulation of aav vector transgene expression
MX2019005266A (es) Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas.
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
MX2020012816A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
MX349601B (es) Remocion de virus contaminantes de preparaciones de aav.
WO2014025771A3 (en) Methods and compositions for inactivating enveloped viruses
WO2014144632A3 (en) Human pac1 antibodies
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144